• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib.

作者信息

Sandova Veronika, Pavlasova Gabriela Mladonicka, Seda Vaclav, Cerna Katerina Amruz, Sharma Sonali, Palusova Veronika, Brychtova Yvona, Pospisilova Sarka, Fernandes Stacey M, Panovska Anna, Doubek Michael, Davids Matthew S, Brown Jennifer R, Mayer Jiri, Mraz Marek

机构信息

Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

出版信息

Haematologica. 2021 Nov 1;106(11):2995-2999. doi: 10.3324/haematol.2021.278644.

DOI:10.3324/haematol.2021.278644
PMID:34196167
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8561290/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa77/8561290/5e4f3305b552/1062995.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa77/8561290/83390f35d648/1062995.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa77/8561290/10a3897eef77/1062995.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa77/8561290/5e4f3305b552/1062995.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa77/8561290/83390f35d648/1062995.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa77/8561290/10a3897eef77/1062995.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa77/8561290/5e4f3305b552/1062995.fig3.jpg

相似文献

1
IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib.IL4-STAT6信号通路在慢性淋巴细胞白血病中诱导CD20表达，而该信号轴被PI3Kδ抑制剂idelalisib所抑制。
Haematologica. 2021 Nov 1;106(11):2995-2999. doi: 10.3324/haematol.2021.278644.
2
Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.依鲁替尼治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。
Future Oncol. 2016 Sep;12(18):2077-94. doi: 10.2217/fon-2016-0003. Epub 2016 Jun 21.
3
Idelalisib.idelalisib（依地利斯布）
Recent Results Cancer Res. 2018;212:243-264. doi: 10.1007/978-3-319-91439-8_12.
4
Idelalisib: targeting PI3Kδ in B-cell malignancies.idelalisib：靶向B细胞恶性肿瘤中的PI3Kδ
Lancet Oncol. 2014 Mar;15(3):e108. doi: 10.1016/s1470-2045(14)70052-x.
5
Idelalisib--a PI3Kδ inhibitor for B-cell cancers.idelalisib——一种用于治疗B细胞癌症的PI3Kδ抑制剂。
N Engl J Med. 2014 Mar 13;370(11):1061-2. doi: 10.1056/NEJMe1400055.
6
Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.血液系统癌症：idelalisib靶向B细胞恶性肿瘤患者的PI3Kδ
Nat Rev Clin Oncol. 2014 Apr;11(4):184-6. doi: 10.1038/nrclinonc.2014.42. Epub 2014 Mar 18.
7
Idelalisib Rescues Natural Killer Cells from Monocyte-Induced Immunosuppression by Inhibiting NOX2-Derived Reactive Oxygen Species.依鲁替尼可通过抑制 NOX2 衍生的活性氧来挽救自然杀伤细胞免受单核细胞诱导的免疫抑制。
Cancer Immunol Res. 2020 Dec;8(12):1532-1541. doi: 10.1158/2326-6066.CIR-20-0055. Epub 2020 Sep 23.
8
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.idelalisib：用于治疗慢性淋巴细胞白血病、小淋巴细胞白血病和滤泡性淋巴瘤的首款PI3Kδ抑制剂。
Clin Cancer Res. 2015 Apr 1;21(7):1537-42. doi: 10.1158/1078-0432.CCR-14-2034. Epub 2015 Feb 10.
9
Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia.idelalisib联合利妥昔单抗对慢性淋巴细胞白血病继发的系统性AL淀粉样变性有效。
Hematol Oncol. 2018 Feb;36(1):366-369. doi: 10.1002/hon.2480. Epub 2017 Oct 3.
10
The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.PI3Kδ 选择性抑制剂伊德拉利司他最小程度地干扰利妥昔单抗或奥滨尤妥珠单抗介导的免疫效应功能，并显著增强体内 B 细胞耗竭。
J Immunol. 2018 Apr 1;200(7):2304-2312. doi: 10.4049/jimmunol.1700323. Epub 2018 Feb 16.

引用本文的文献

1
Mannich-Type Condensation and Domino Quinazolinone-Amidine Rearrangement Affords Ring-Fused Mackinazolinones with Anti-Amoebic Activity.曼尼希型缩合反应与多米诺喹唑啉酮-脒重排反应合成具有抗阿米巴活性的稠环麦基那唑啉酮。
Adv Synth Catal. 2023 Dec 19;365(24):4567-4575. doi: 10.1002/adsc.202300994. Epub 2023 Nov 20.
2
Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells.癌症免疫疗法靶向 CD20 的进展：从开创性的单克隆抗体到嵌合抗原受体修饰的 T 细胞。
Front Immunol. 2024 Apr 4;15:1363102. doi: 10.3389/fimmu.2024.1363102. eCollection 2024.
3

本文引用的文献

1
The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy.CD20 的调节和功能：B 细胞生物学和靶向治疗的“谜”。
Haematologica. 2020 Jun;105(6):1494-1506. doi: 10.3324/haematol.2019.243543.
2
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.随机对照试验：伊布替尼对比伊布替尼联合利妥昔单抗治疗慢性淋巴细胞白血病患者。
Blood. 2019 Mar 7;133(10):1011-1019. doi: 10.1182/blood-2018-10-879429. Epub 2018 Dec 7.
3
Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels.
The importance of protein domain mutations in cancer therapy.
蛋白质结构域突变在癌症治疗中的重要性。
Heliyon. 2024 Mar 9;10(6):e27655. doi: 10.1016/j.heliyon.2024.e27655. eCollection 2024 Mar 30.
4
Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies.其 5'-UTR 的可变剪接限制了 CD20 mRNA 的翻译，并使肿瘤对 CD20 导向的免疫疗法产生耐药性。
Blood. 2023 Nov 16;142(20):1724-1739. doi: 10.1182/blood.2023020400.
5
NF-kB and the CLL microenvironment.核因子-κB与慢性淋巴细胞白血病微环境
Front Oncol. 2023 Mar 30;13:1169397. doi: 10.3389/fonc.2023.1169397. eCollection 2023.
6
The application of Interleukin-2 family cytokines in tumor immunotherapy research.白细胞介素-2 家族细胞因子在肿瘤免疫治疗研究中的应用。
Front Immunol. 2023 Mar 2;14:1090311. doi: 10.3389/fimmu.2023.1090311. eCollection 2023.
7
Application and Molecular Mechanisms of Extracellular Vesicles Derived from Mesenchymal Stem Cells in Osteoporosis.间充质干细胞来源的细胞外囊泡在骨质疏松症中的应用及分子机制
Curr Issues Mol Biol. 2022 Dec 15;44(12):6346-6367. doi: 10.3390/cimb44120433.
8
Synthetic selenium nanoparticles as co-adjuvant improved immune responses against methicillin-resistant Staphylococcus aureus.合成硒纳米颗粒作为佐剂增强了耐甲氧西林金黄色葡萄球菌的免疫应答。
World J Microbiol Biotechnol. 2022 Nov 19;39(1):16. doi: 10.1007/s11274-022-03455-6.
9
Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas.白血病和淋巴瘤患儿靶向治疗的感染并发症
Cancers (Basel). 2022 Oct 14;14(20):5022. doi: 10.3390/cancers14205022.
10
Dihydropyrazinoquinazolinones via S2 Sulfamidate Ring-Opening and a Sequential Quinazolinone-Amidine Rearrangement Strategy (SQuAReS).通过 S2 磺酰胺环开裂和顺序喹唑啉酮-脒重排策略（SQuAReS）合成二氢吡嗪并喹唑啉酮。
J Org Chem. 2022 Nov 4;87(21):14889-14898. doi: 10.1021/acs.joc.2c01717. Epub 2022 Oct 4.
利妥昔单抗主要靶向以高CD20水平为特征的克隆内BCR信号传导功能正常的慢性淋巴细胞白血病亚群。
Leukemia. 2018 Sep;32(9):2028-2031. doi: 10.1038/s41375-018-0211-0. Epub 2018 Jul 20.
4
FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy.FOXO1促进非霍奇金淋巴瘤对基于抗CD20治疗的耐药性。
Oncoimmunology. 2018 Jan 25;7(5):e1423183. doi: 10.1080/2162402X.2017.1423183. eCollection 2018.
5
Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.依鲁替尼抑制由CXCR4/SDF-1轴介导的慢性淋巴细胞白血病B细胞上CD20的上调。
Blood. 2016 Sep 22;128(12):1609-13. doi: 10.1182/blood-2016-04-709519. Epub 2016 Aug 1.
6
IL-4 rescues surface IgM expression in chronic lymphocytic leukemia.白细胞介素-4可挽救慢性淋巴细胞白血病中的表面免疫球蛋白M表达。
Blood. 2016 Jul 28;128(4):553-62. doi: 10.1182/blood-2015-11-682997. Epub 2016 May 25.
7
Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.伊布替尼与抗CD20抗体之间的相互作用：对联合治疗结果的竞争效应。
Clin Cancer Res. 2016 Jan 1;22(1):86-95. doi: 10.1158/1078-0432.CCR-15-1304. Epub 2015 Aug 17.
8
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.依鲁替尼干扰治疗性CD20抗体的细胞介导抗肿瘤活性：对联合治疗的启示。
Haematologica. 2015 Jan;100(1):77-86. doi: 10.3324/haematol.2014.107011. Epub 2014 Oct 24.
9
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.依鲁替尼联合利妥昔单抗治疗复发慢性淋巴细胞白血病。
N Engl J Med. 2014 Mar 13;370(11):997-1007. doi: 10.1056/NEJMoa1315226. Epub 2014 Jan 22.
10
Reduced T-dependent humoral immunity in CD20-deficient mice.CD20 缺陷型小鼠 T 依赖性体液免疫应答降低。
J Immunol. 2013 Sep 15;191(6):3112-8. doi: 10.4049/jimmunol.1202098. Epub 2013 Aug 21.